Scroll

miconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
systemic antifungal agents, miconazole derivatives	1800	22916-47-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: miconazole miconazole nitrate	An imidazole antifungal agent that is used topically and by intravenous infusion. Molecular weight: 416.12 Formula: C18H14Cl4N2O CLOGP: 5.81 LIPINSKI: 1 HAC: 3 HDO: 0 TPSA: 27.05 ALOGS: -5.74 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

miconazole
miconazole nitrate

An imidazole antifungal agent that is used topically and by intravenous infusion.

Molecular weight: 416.12
Formula: C18H14Cl4N2O
CLOGP: 5.81
LIPINSKI: 1
HAC: 3
HDO: 0
TPSA: 27.05
ALOGS: -5.74
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O
1	g	O
0.10	g	V
1	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	9.48 mL/min/kg	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	7.14 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	19.75 hours	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	144.18 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
fu (Fraction unbound in plasma)	0.08 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1985	PMDA
Jan. 8, 1974	FDA	INSIGHT PHARMS

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
International normalised ratio increased	230.42	16.01	103	5710	46322	63436887
Drug interaction	183.63	16.01	158	5655	228973	63254236
Hydronephrosis	67.02	16.01	28	5785	10634	63472575
Cholestasis of pregnancy	58.57	16.01	15	5798	1210	63481999
Vulvovaginal burning sensation	46.18	16.01	14	5799	2095	63481114
Haemorrhage subcutaneous	45.38	16.01	15	5798	2968	63480241
Encephalitis fungal	44.34	16.01	7	5806	43	63483166
Haematuria	40.53	16.01	28	5785	29129	63454080
Cancer pain	40.42	16.01	14	5799	3191	63480018
Pericardial effusion	39.76	16.01	28	5785	30030	63453179

Showing 1 to 10 of 41 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
International normalised ratio increased	169.69	18.87	84	3143	47243	34906461
Drug interaction	147.71	18.87	139	3088	225807	34727897
Coagulation time prolonged	29.98	18.87	9	3218	1293	34952411
Haematuria	28.97	18.87	29	3198	50037	34903667
Oedema genital	27.93	18.87	7	3220	513	34953191
Ocular myasthenia	27.74	18.87	6	3221	230	34953474
Genital rash	22.39	18.87	6	3221	572	34953132
Pharyngeal haematoma	21.72	18.87	4	3223	66	34953638
Haemorrhage subcutaneous	21.17	18.87	8	3219	2316	34951388

Showing 1 to 9 of 9 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
International normalised ratio increased	307.10	15.99	154	7572	84567	79652095
Drug interaction	242.47	15.99	246	7480	414937	79321725
Cholestasis of pregnancy	50.89	15.99	13	7713	980	79735682
Hydronephrosis	49.54	15.99	27	7699	17427	79719235
Haematuria	47.68	15.99	45	7681	68791	79667871
Cancer pain	39.72	15.99	16	7710	5229	79731433
Sepsis neonatal	35.85	15.99	6	7720	52	79736610
Nail dystrophy	31.77	15.99	9	7717	1004	79735658
Pericardial effusion	29.68	15.99	29	7697	46208	79690454
Hypokalaemia	27.85	15.99	50	7676	143990	79592672

Showing 1 to 10 of 37 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A01AB09	ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment
ATC	A07AC01	ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Imidazole derivatives
ATC	D01AC02	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives
ATC	D01AC52	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives
ATC	G01AF04	GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives
ATC	J02AB01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Imidazole derivatives
ATC	S02AA13	SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:75282	ergosterol biosynthesis inhibitors
CHEBI has role	CHEBI:82891	glucocorticoid receptor antagonists

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Tinea pedis	indication	6020002	DOID:12403
Candidiasis of skin	indication	49883006
Pityriasis versicolor	indication	56454009	DOID:9060
Candidal vulvovaginitis	indication	72605008	DOID:2272
Candidiasis of mouth	indication	79740000	DOID:14262
Tinea corporis	indication	84849002
Diaper rash	indication	91487003
Tinea cruris	indication	399029005
Onychomycosis due to dermatophyte	indication	402134005
Deep mycosis	indication	716203000

Showing 1 to 10 of 13 entries

Previous1 2Next

🐶 Veterinary Drug Use

Show entries

Search:

Species	Use	Relation
Cats	Infections caused by Microsporum canis	Indication
Cats	Infections caused by Microsporum gypseum	Indication
Cats	Infections caused by Trichophyton mentagrophytes	Indication
Dogs	Infections caused by Microsporum canis	Indication
Dogs	Infections caused by Microsporum gypseum	Indication
Dogs	Infections caused by Trichophyton mentagrophytes	Indication

Showing 1 to 6 of 6 entries

Previous1Next

🐶 Veterinary products

Show entries

Search:

Product	Applicant	Ingredients
Conofite Cream 2%	Intervet Inc.	1
Conofite Lotion 1%	Intervet Inc.	1
Easotic	Virbac AH Inc.	3
Miconosol	Med-Pharmex Inc.	1
Priconazole Lotion 1% and Spray 1%	First Priority Inc.	1
Surolan	Elanco US Inc.	3

Showing 1 to 6 of 6 entries

Previous1Next

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.49	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.25%;81.35%;15%	VUSION	MYLAN	N021026	Feb. 16, 2006	RX	OINTMENT	TOPICAL	8147852	March 30, 2028	USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS

Showing 1 to 1 of 1 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	Ki	5.14	DRUG MATRIX
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	IC50	4.59	DRUG MATRIX
Cannabinoid receptor 1	GPCR	P21554	CNR1_HUMAN	Ki	4.78	DRUG MATRIX
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	Ki	5.61	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	Ki	5.51	DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	Ki	5.38	DRUG MATRIX
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN	Ki	5.10	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	Ki	5.83	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN			WOMBAT-PK
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN	IC50	7	DRUG MATRIX

Showing 1 to 10 of 70 entries

Previous1 2 3 4 5 6 7Next

External reference:

Show entries

Search:

ID	Source
002918	NDDF
002919	NDDF
1135	MMSL
22832-87-7	SECONDARY_CAS_RN
2449	IUPHAR_LIGAND_ID
2728	INN_ID
36502	MMSL
372738006	SNOMEDCT_US
4018554	VANDF
4018555	VUID

Showing 1 to 10 of 28 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Antifungal	HUMAN OTC DRUG LABEL	1	0472-0735	CREAM	20 mg	TOPICAL	OTC monograph final	13 sections
Antifungal	HUMAN OTC DRUG LABEL	1	0472-0735	CREAM	20 mg	TOPICAL	OTC monograph final	13 sections
Athletes Foot	HUMAN OTC DRUG LABEL	1	0363-0557	SPRAY	2 g	TOPICAL	OTC monograph final	13 sections
basic care miconazole 3	HUMAN OTC DRUG LABEL	1	0113-7070	CREAM	40 mg	VAGINAL	ANDA	17 sections
basic care miconazole 7	HUMAN OTC DRUG LABEL	1	0113-7825	CREAM	2 g	VAGINAL	ANDA	17 sections
Desenex	HUMAN OTC DRUG LABEL	1	0316-0225	POWDER	20 mg	TOPICAL	OTC monograph final	13 sections
Good Sense Miconazole 7	HUMAN OTC DRUG LABEL	1	0113-0214	CREAM	2 g	VAGINAL	ANDA	17 sections
good sense miconazole 7	HUMAN OTC DRUG LABEL	1	0113-0825	CREAM	2 g	VAGINAL	ANDA	17 sections
Jock Itch	HUMAN OTC DRUG LABEL	1	0363-1497	SPRAY	2 g	TOPICAL	OTC monograph final	13 sections
miconazole 3	HUMAN OTC DRUG LABEL	1	0363-2070	CREAM	40 mg	VAGINAL	ANDA	17 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next